4.4 Review

Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis

Journal

SYSTEMATIC REVIEWS
Volume 10, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13643-021-01599-4

Keywords

Low back pain; Antidepressants; Analgesics; Druq therapy; Review; Meta-analysis

Funding

  1. Australian Medical Research Future Fund [GNTID1170205]
  2. NeuRA
  3. Australian Government Research Training Program Scholarship
  4. UNSW Research Excellence Award
  5. University Postgraduate Award from the University of New South Wales
  6. School of Medical Sciences Top-Up Scholarship from the University of New South Wales
  7. Postgraduate Scholarship from the National Health and Medical Research Council of Australia
  8. University of New South Wales Prince of Wales Clinical School Postgraduate Research Scholarship
  9. NeuRA PhD Candidature Supplementary Scholarship
  10. Australian Government post-graduate award
  11. University of New South Wales School of Medical Sciences Postgraduate Research Scholarship

Ask authors/readers for more resources

This study evaluated the efficacy and safety of antidepressant medicines for low back pain, finding that antidepressants have a small effect on reducing pain intensity but increase the odds of stopping treatment, affecting acceptability.
Background: Antidepressant medicines are used to manage symptoms of low back pain. The efficacy, acceptability, and safety of antidepressant medicines for low back pain (LBP) are not clear. We aimed to evaluate the efficacy, acceptability, and safety of antidepressant medicines for LBP. Methods: We searched CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov , the EU Clinical Trials Register, and the WHO International Clinical Trial Registry Platform from inception to May 2020. We included published and trial registry reports of RCTs that allocated adult participants with LBP to receive an antidepressant medicine or a placebo medicine. Pairs of authors independently extracted data in duplicate. We extracted participant characteristics, study sample size, outcome values, and measures of variance for each outcome. We data using random-effects meta-analysis models and calculated estimates of effects and heterogeneity for each outcome. We formed judgments of confidence in the evidence in accordance with GRADE. We report our findings in accordance with the PRISMA statement. We prespecified all outcomes in a prospectively registered protocol. The primary outcomes were pain intensity and acceptability. We measured pain intensity at end-of-treatment on a 0-100 point scale and considered 10 points the minimal clinically important difference. We defined acceptability as the odds of stopping treatment for any reason. Results: We included 23 RCTs in this review. Data were available for pain in 17 trials and acceptability in 14 trials. Treatment with antidepressants decreased pain intensity by 4.33 points (95% CI - 6.15 to - 2.50) on a 0-100 scale, compared to placebo. Treatment with antidepressants increased the odds of stopping treatment for any reason (OR 1.27 [95% CI 1.03 to 1.56]), compared to placebo. Conclusions: Treatment of LBP with antidepressants is associated with small reductions in pain intensity and increased odds of stopping treatment for any reason, compared to placebo. The effect on pain is not clinically important. The effect on acceptability warrants consideration. These findings provide Level I evidence to guide clinicians in their use of antidepressants to treat LBP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available